title: Herpes zoster complicating bortezomib therapy of relapsed/refractory indolent B-cell and mantle cell lymphoma: an analysis of two phase II trials.
abstract: The incidence of herpes zoster (HZ) in patients with non-Hodgkin lymphoma (NHL) receiving bortezomib-based therapy has not been well studied. We reviewed data from two phase II trials in which bortezomib was administered to 236 patients, median age 65 years, with relapsed/refractory mantle cell or indolent NHL. HZ occurred in 24 patients (10.2%) overall, with a comparable incidence in NHL histologic subgroups. Median time to HZ was 39 (range, 11-206) days. In total, 71% of patients who developed HZ were aged ≥ 65 years, compared to 48% without HZ (p = 0.03). Patients with HZ were more likely to have had received ≥ 2 lines of therapy (63% vs. 47%, p = 0.16). Six (25%) of the patients who developed HZ had received purine analogs, compared with 34 (16%) patients without HZ (p = 0.27). As the occurrence of HZ may complicate the course of indolent or mantle cell NHL in patients receiving bortezomib-based therapies, these patients, especially the elderly, should be strongly considered for antiviral prophylaxis.
authors: Florida Center for Cellular Therapy, Florida Hospital Cancer Institute , Orlando, FL , USA.
authors: Melhem
authors: M
authors: Solh
authors: Richard I
authors: RI
authors: Fisher
authors: André
authors: A
authors: Goy
authors: Sven
authors: S
authors: de Vos
authors: Steven H
authors: SH
authors: Bernstein
authors: Dixie-Lee
authors: DL
authors: Esseltine
authors: Rachel
authors: R
authors: Neuwirth
authors: Vicki A
authors: VA
authors: Morrison
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001897:Boronic Acids / Q000008:administration & dosage; D000069286:Bortezomib; D005260:Female; D006562:Herpes Zoster / Q000150:complications* / Q000209:etiology; D006801:Humans; D016393:Lymphoma, B-Cell / Q000150:complications* / Q000188:drug therapy* / Q000473:pathology; D020522:Lymphoma, Mantle-Cell / Q000150:complications* / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011719:Pyrazines / Q000008:administration & dosage; D012008:Recurrence; D012307:Risk Factors
chemical_list: D001897:Boronic Acids; D011719:Pyrazines; D000069286:Bortezomib